Understanding how certain drugs can harm the liver using patient-derived liver models.
Modeling Drug Induced Liver Injury with Patient-Derived Liver Organoids and Microfluidic Chips
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11018632
This study is looking at how certain medications can harm the liver, especially for people who have had liver problems before, by using tiny lab-grown liver models to find safer drug options and better understand how liver damage happens.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11018632 on ClinicalTrials.gov |
What this research studies
This research investigates drug-induced liver injury (DILI), a serious condition that can lead to acute liver failure. By utilizing patient-derived liver organoids and advanced microfluidic technology, the study aims to create a predictive platform that can better assess the risk of liver damage from various medications. The approach involves collecting liver cells from patients who have experienced DILI and using them to model liver responses to drugs in a controlled environment. This innovative method seeks to enhance our understanding of liver injury mechanisms and identify safer drug options.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced drug-induced liver injury or are at risk of liver damage from medications.
Not a fit: Patients who have not experienced liver injury or do not take medications that could potentially cause liver damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of safer medications and improved risk prediction for liver injury in patients.
How similar studies have performed: Previous research has shown promise in using patient-derived models to study drug toxicity, indicating that this approach could yield valuable insights.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SEXTON, JONATHAN ZACHARY — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: SEXTON, JONATHAN ZACHARY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: acute hepatic disease, acute liver disease